GlaxoSmithKline, Fred Hutchinson deal
GlaxoSmithKline and the research center partnered under GSK's Discovery Partnerships with Academia to develop products to treat facioscapulohumeral muscular dystrophy (FSHD). The center will receive an undisclosed upfront payment and research expenses and is eligible for undisclosed milestones and royalties. GSK and researchers at the center led by the its Fred Hutch Human Biology Division will be responsible for working on the collaboration, which aims to build on work led by the division on a protein that is incorrectly expressed by the double homeobox 4 (DUX4) gene in people with the disease. The partners aim to reverse FSHD by developing a small molecule-based medicine to inhibit the protein. The partners did not disclose financial details. ...